Literature DB >> 1525633

Ophthalmological screening in juvenile arthritis: should the frequency of screening be based on the risk of developing chronic iridocyclitis?

T R Southwood1, C A Ryder.   

Abstract

Chronic iridocyclitis (CI) may complicate juvenile chronic arthritis (JCA) and if left untreated may cause significant ocular impairment. It is usually not symptomatic and diagnosis relies on slit lamp biomicroscopy. It is unclear how often children with JCA should be screened for this complication. From a review of the literature, the following recommendations could be made, although these require scientific validation. All children with JCA should have at least one adequate slit lamp examination as soon as possible after diagnosis of the arthritis. If CI is detected then appropriate treatment and follow up should be determined by the ophthalmologist. If CI is not detected initially, all children with JCA should be screened by slit lamp examinations every 3-4 months for the first 5 years after arthritis onset. After 5 years, CI screening could be stopped. The only exceptions would be arthritic children at low risk for CI, including systemic onset JCA, juvenile spondyloarthropathy and juvenile onset rheumatoid arthritis, who do not need to be screened if the initial slit lamp examination is normal.

Entities:  

Mesh:

Year:  1992        PMID: 1525633     DOI: 10.1093/rheumatology/31.9.633

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  9 in total

1.  An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood.

Authors:  Clive Edelsten; Vickie Lee; Christopher R Bentley; Jack J Kanski; Elizabeth M Graham
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

Review 2.  Current approach in diagnosis and management of anterior uveitis.

Authors:  Rupesh V Agrawal; Somasheila Murthy; Virender Sangwan; Jyotirmay Biswas
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

Review 3.  Noninfectious immune-mediated uveitis and ocular inflammation.

Authors:  Jennifer Pan; Manuj Kapur; Rex McCallum
Journal:  Curr Allergy Asthma Rep       Date:  2014-01       Impact factor: 4.806

4.  Managing the complications of childhood arthritis.

Authors:  T Southwood
Journal:  BMJ       Date:  1995-09-23

Review 5.  Inflammatory conditions of the eye associated with rheumatic diseases.

Authors:  N A Afshari; M A Afshari; C S Foster
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

Review 6.  Advances in biomarkers for paediatric rheumatic diseases.

Authors:  Alessandro Consolaro; Giulia C Varnier; Alberto Martini; Angelo Ravelli
Journal:  Nat Rev Rheumatol       Date:  2014-12-16       Impact factor: 20.543

7.  Juvenile idiopathic arthritis-associated uveitis: Data from a region in western Greece.

Authors:  Ioannis Asproudis; Taxiarchis Felekis; Elena Tsanou; Spiridon Gorezis; Eikaterini Karali; Sapfo Alfantaki; Antigoni Siamopoulou-Mauridou; Miltiadis Aspiotis
Journal:  Clin Ophthalmol       Date:  2010-04-26

Review 8.  Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis.

Authors:  Francesco Semeraro; Barbara Arcidiacono; Giuseppe Nascimbeni; Martina Angi; Barbara Parolini; Ciro Costagliola
Journal:  Drug Des Devel Ther       Date:  2014-03-24       Impact factor: 4.162

9.  Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative.

Authors:  Tamas Constantin; Ivan Foeldvari; Jordi Anton; Joke de Boer; Severine Czitrom-Guillaume; Clive Edelsten; Raz Gepstein; Arnd Heiligenhaus; Clarissa A Pilkington; Gabriele Simonini; Yosef Uziel; Sebastian J Vastert; Nico M Wulffraat; Anne-Mieke Haasnoot; Karoline Walscheid; Annamária Pálinkás; Reshma Pattani; Zoltán Györgyi; Richárd Kozma; Victor Boom; Andrea Ponyi; Angelo Ravelli; Athimalaipet V Ramanan
Journal:  Ann Rheum Dis       Date:  2018-03-28       Impact factor: 19.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.